Regado Biosciences, Inc.

Iveric Bio, Inc.

Tobira Therapeutics, Inc.

Douglas Brooks

Christopher P Rusconi

Juliana Layzer

Richard Everett

Samir Patel

Steven Zelenkofske

Shane Xinxin Tian

Steven L Zelenkofske

Juliana M Layzer

The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Methods for treating or preventing ophthalmological conditions

The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

Nucleic acid modulators of glycoprotein VI

Growing community of inventors

Durham, NC, United States of America

Douglas Brooks